阿斯匹林療效類抗凝血藥

這份刊登於「新英格蘭醫學期刊」（New England Journal of Medicine）的研究，歷經 10 年重要臨床實驗，以及追蹤11 國 2,305 名病患才完成。

The investigators designed this trial to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better treatment for patients in sinus rhythm who have a reduced left ventricular ejection fraction (LVEF). They followed 2305 patients for up to 6 years (mean [±SD], 3.5±1.8). The primary outcome was the time to the first event in a composite end point of ischemic stroke, intracerebral hemorrhage, or death from any cause.

Among patients with reduced LVEF who were in sinus rhythm, there was no significant overall difference in the primary outcome between treatment with warfarin and treatment with aspirin. A reduced risk of ischemic stroke with warfarin was offset by an increased risk of major hemorrhage. The choice between warfarin and aspirin should be individualized.

研究指出，有些證據顯示，研究人員追蹤服用 Warfarin 的患者 4 年或以上後發現，Warfarin 在預防死亡、中風或腦出血的表現較優，但仍須更多分析佐證。